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Macrophages secrete fibronectin (Fn)' (1-3), bind Fn (3-5), and have been
reported to migrate in response to Fn fragments (6). In addition, the interaction
of human macrophages with Fn provides a second signal that leads to enhanced
complement and Fcreceptor-mediated phagocytosis by thesecells (7-14). The structure
ofthe Fnreceptor, orreceptors, responsible forboth adherenceto Fn andFn-mediated
phagocytosis enhancement in macrophages is not completely understood. Previous
studieshave demonstrated membrane proteinson monocytes orculture-derived mac-
rophages that interact with the 110-kD cell-binding domain of Fn (15). These pro-
teins exhibit electrophoretic mobility typical ofthe recently described Fn receptor,
termed VLA-5, purified from placenta, fibroblasts, theMG63 osteosarcoma cell line,
erythroblasts, and platelets(reviewed inreferences 16-18). This receptor is ahetero-
dimer consisting of an ti150-kD a chain and a 130-kD a chain under nonreducing
conditions (19). Identification and sequence analysis ofcDNA clones for bothchains
from a placental cDNA library has placed this receptor in the integrin family (18,
20), whose members function in cellular adhesion. The VLA antigens form a part
ofthis family and are defined by having a common R chain that can noncovalently
combine with at least six distinct a chains (21-24). We have recently demonstrated
by Northern blot analysis the presence of mRNA that hybridizes with probes for
both the VLA-5 a and the common VLA (3 chain in monocytes, as well as in the
monocyte-like cell lines HL-60, THP, and U937 (25). In addition, partial cDNA
clones that we have isolated from an HL-60 libraryhave shown identical restriction
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endonuclease maps and derived amino acid sequence, thus far, when compared with
VLA-5 (25), confirming that mononuclear phagocytes express this Fn receptor. How-
ever, several studies have identified other, less well-characterized, RGD-binding pro-
teins that also may be involved in monocyte or macrophage binding to Fn (15, 26-29).
Therefore, it appears likely that at least two, and possibly more, receptors for Fn
are present on monocytes.
The specific role that VLA-5 plays in macrophage biology is not defined. Fn is
increased in granulation tissue (30), in healing wounds (31), and in extravascular
deposits in inflammatory foci (32) . Mediation of adherence and/or chemotaxis (33)
to these sites is one likely but unproven role for this receptor. To gain further insight
into the in vivo biology of phagocyte Fn receptors, we have begun an analysis of
the Fn receptors expressed in murine peritoneal macrophages . Here we present a
partial sequence analysis of the a chain and complete sequence analysis of the (3
chain of the murine Fn receptor heterodimer that is the homologue of VLA-5. In
addition, we have used three well-characterized models of macrophage activation
in murine peritoneal exudate cells (PECs) to determine whether VLA-5 a and a
chain mRNA and protein expression can be modulated in response to in vivo inflam-
matory stimuli.
Materials and Methods
Mice.
￿
Pathogen-free BALB/c retired breeders were obtained from Harlan-Sprague Dawley,
Inc. (Indianapolis, IN) for use in resident, peptone, and thioglycollate-elicited experiments.
BALB/c mice used for PEC elicitation using Listeria monocytogenes were obtained from
Jackson Laboratories (Bar Harbor, ME), and 10-d Listeria infected, as well as uninfected,
control mice were generously provided by Paul Allen (Washington University, St. Louis, MO).
Library Construction and Identification of Clones. To construct a cDNA library from perito-
neal macrophages, cells elicited using thioglycollate were harvested from 60 BALB/c mice
at day 3. Total RNA was isolated using the guanidine isothiocyanate, cesium chloride
(GITC/CsCl) method (34). Poly(A)' mRNA was isolated using oligo-dTzSepharose chroma-
tography. A cDNA library was constructed using the RNAse H-Pol I method (35) and cloned
into Xgt10 after size selection of >1.0 kb. Human cDNA Fn receptor a and (3 chain probes
isolated from an HL-60 cDNA library (25) were labeled by the random primed method (36).
The HL-60 cDNA clones were initially obtained by hybridization at high stringency with
a partial cDNA provided by S. Argraves and E. Ruoslahti (LaJolla Cancer Research Founda-
tion, LaJolla, CA) (37) for the VLA-5 a chainand at intermediate stringency with a chicken
integrin probe provided by R. Hynes (Massachusetts Institute of Technology, Cambridge,
MA) (38) for the VLA /3 chain. Approximately 150,000 amplified recombinant PEC phage
clones were probed sequentially initially at high stringency in a buffer containing 5 x SSC
(1 x = 0.15 M NaCl/0.015 M sodium citrate/0.05 M sodium phosphate, pH 6.5)/l x Den-
hardt's solution (1 x = 0.02% Ficoll 400/0.02% polyvinylpyrolidone /0.02% BSA)/50%
(vol/vol) formamide/12.5% dextran sulfate/denatured herring sperm DNA (0.1 mg/ml) at 42°C.
Blots were then washed at 56°C in a buffer containing 0.2 x SSC/0.1 % SDS, and autoradio-
graphs were developed usingKodak XAR5 film. The library was further analyzed with the
same probes at a lower stringency, in the same conditions, except formamide (30%) and tem-
perature (37°C) and was washed at 37'C in 2 x SSC/0.1% SDS.
Subclone and Sequence Analysis.
￿
Phage clones hybridizing to probes were plaque purified
and inserts subcloned into the Bluescript plasmid (Stratagene, San Diego, CA). Because some
Eco Rl ends were damaged during cloning, flanking Hind III and BgI II sites in Xgtl0 were
used to isolate these particular inserts. Clones were sequenced using the Sanger method and
modified T7 polymerase(Sequenase; U.S. Biochemical, Cleveland, OH). Specific sequencing
oligonucleotides were constructed using the phosphoramidite method (39). Sequence anal-
ysis was performed using Microgenie software (Beckman Instruments, Inc., Palo Alto, CA).HOLERS ET AL.
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Northern Blot Analysis.
￿
Total RNA was isolated from tissues and elicited cells using the
GITC/CsCl method. Adherent peritoneal macrophages were first treated with GITC and
then scraped completely. Northern blot electrophoresis was performed using 0.9% agarose/
0.6% formaldehyde gels in a buffer containing 0.02 M 3-(N-morpholino) propanesulfonic
acid, 5 mM sodium acetate, and 1 mM EDTA (disodium salt) in 0.03 p,g/ml ethidium bro-
mide. To assure complete and equal transfer ofRNA to the membrane, RNA was electropho-
retically transferred to nylon membranes (Micron Systems, Inc., Honeyone Falls, NY). Com-
pleteness of transfer was assured by lack of residual RNA staining in the gel and the
demonstration of transfer of ethidium bromide-stained RNA to the nylon. cDNA probes
as noted below were labeled by the random primed method (36), and blots were hybridized
and washed in the same high stringency buffers as above. Blots were dehybridized and reused
to obtain quantitative data on relative expression. Quantitation ofrelative transcript expres-
sion was performed usinglaserdensitometry (Ultrascan XL; LKB Instruments, Inc., Gaithers-
burg, MD), and densitometric values were normalized to 1.0 relative to resting total PECs
or adherent macrophages for comparison studies.
cDNA Probes.
￿
Plasmids pBSMFNRot-1.4 and pBSMFNR/3-3 are as described in results.
The /3-actin probe is the chicken /3-actin cDNA (40) and was provided by J. Milbrandt
(Washington University). The Ia probe utilized is the IAd a chain cDNA of Davis et al. (41)
and was provided by K. Murphy (Washington University). The CHO-B cDNA was isolated
from Chinese hamster cells (42) and is a gene transcribed ubiquitously with no known modu-
lators of transcription. This was provided by D. Dean (Washington University) and was iso-
lated initially in the laboratory of R. Evans (Salk Institute, La Jolla, CA).
Generation andIsolation ofPeritoneal Cells.
￿
Toelicit peritoneal cells, either 1 ml of 107o pep-
tone (Difco Laboratories Inc., Detroit, MI), 1 ml of 10% thioglycollate broth (Difco Labora-
tories Inc.), or 100,000 live Listeria monocytogenes were injected intraperitoneally at various
time points before isolation of cells. Unless otherwise stated, peritoneal cells were isolated
at 72-96 h using peptone or thioglycollate and at 10 d using Listeria. Resting and elicited
peritoneal cells were isolated by irrigation of the peritoneum with sterile cold PBS with 1%
FCS. Similar to previous reports, the total intraperitoneal cell population increased two- to
eightfold upon addition of these inflammatory stimuli (43). Assessment of cell viability by
trypan blue exclusion demonstrated >95% viability in all experiments and usually >99%.
Adherent macrophages and nonadherent cells were separated by attachmentof isolated PECs
to polystyrene tissue culture dishes (Corning Glass Works, Corning, NY) for 2 h at 37'C
in a buffer containing DME with 1% FCS in a 5% C02 incubator. Nonadherent cells were
removed by vigorous rinsing with PBS three times.
Surface Iodination, Solubilization, and Immunoprecipitation.
￿
Resting and thioglycollate elicited
macrophages were purified by adherence, removed by scraping, counted, and surface labeled
with ' 25Iodine (New England Nuclear, Boston, MA) using the lactoperoxidase method (44).
3 x 10' cells of each were solubilized in PBS with 1% NP-40 and protease inhibitors as
reported previously (44). After removal of insoluble material by centrifugation at 12,000 ,g,
immunoprecipitation ofequal cell number aliquots of solubilized membranes was performed.
Ab33, a rabbit polyclonal antibody raised to the COOH-terminal 11 amino acidsofthe human
VLA-5a chain sequence, was used in these studies afteraffinity purification. Ab33 specifically
and quantitatively immunoprecipitates VLA-5 from IMR90 fibroblasts and localizes with
Fn in immunofluorescent studies ofthese cells (44a) . Control nonimmune rabbit Ig was used
in equal quantities. Equal cell number aliquots of immunoprecipitated material was ana-
lyzed by reducing and nonreducing SDS-PAGE using 7.5 9 Io acrylamide followed by autora-
diography. Reduction of samples was performed using 5% 2-ME at 80'C for 5 min.
Results
Mouse Fn Receptor ce and,B Chain cDNA Isolation.
￿
Using cDNA probes for both
VLA-5 a and 0 chains that we had isolated from HL-60 cells, we examined a mouse
thioglycollate-elicited PEC library at both high and intermediate stringency. Three
ct chain-related and three R chain-related cDNAs were identified by this method
at high stringency, and no further clones were identified at a lower stringency.1592
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Sequence analysis of the longest a chain-related clone, XMFNRci-4, indicated
that it was a partial cDNA (Fig. 1 a). The cDNA encoded an open reading frame
that was highly homologous to the COOH-terminal 408 amino acids of the human
placentalVLA-5 (VLA-5a) a chain sequence (20). The overallhomology, when com-
pared with the corresponding coding region of the human cDNA sequence (Fig.
a AMFrR.A4 j
500bp
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ison. 10 of the amino acid differences are conservative, and there is one extra serine
codon in the mouse sequence. The 10 cysteines present in the comparable human
sequence are conserved. Interestingly, the predicted intracytoplasmic domain se-
quence of XMFNRa-1 .4 is identical to the human a chain sequence. While this
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1.4 are shown above and the
nucleotide and derived protein
sequence below . The transmem-
brane sequence is boxed, and
the intracytoplasmic sequence
is underlined. Potential N-linked
glycosylation sites are shown by
asterisks. (b) Comparison be-
tween the mouse and human a
chain sequences. The trans-
membrane region is boxed, and
the identical intracytoplasmic
sequences are underlined. The
position of the lysine-arginine
dipeptide that precedes the
putative cleavage site is shown
by a box. Conserved cysteines
are shown by arrowheads. These
sequence data have been sub-
mitted to the EMBL/GenBank
Data Libraries under the acces-
sion number Y00818 .1594
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EXPRESSION OF MURINE PERITONEAL MACROPHAGE VLA-5
observation has been made when comparing 0 chain sequence across species (45,
46), this is the first demonstration ofan a chain intracytoplasmic sequence identity
across species. Taken together, this very highdegree ofhomology is strong evidence
that XMFNRoi-1.4 encodes the mouse homologue ofVLA-5a.
20 ofthe 42 sequence differences between the mouse and human VLA-5a chain
are clustered in 71 amino acids from the lysine at position 863 to the arginine at
932 (numbering by human sequence). These flank the presumed a chain cleavage
site at the arginine-glutamic acid peptide bond at position 894-895. In spite ofthe
sequence differences, comparison of hydrophobicity by the method of Kyte and
Doolittle (47) about that site reveals no significantdifferences. Moreover, like human
VLA-5a, the mouse a chain undergoes a post-translational cleavage (see below).
Analysis ofthe longest 0 chain-related cDNA identified 3,491 nucleotides with
averyhigh degree ofhomology to thehuman(3(VLA R) chain sequence (20), which
included the entire translated sequence with the exception ofthe initiating adeno-
sine ofthe methionine codon (Fig. 2 a). Two potential polyadenylation sites are un-
derlined, one near the 3' end and one -600 nucleotides 5' ofthis. Comparison of
mouse to human sequence in the translatedregion (Fig. 2 b) indicates ahigh degree
ofconservation in the coding region in both nucleotide (90%) and derived amino
acid sequence (92%). 26 ofthe 67 amino aciddifferences are conservative, and there
is one extra serine in the mouse sequence. All 56 cysteines are conserved, and the
intracytoplasmic sequence is identical to the human VLA 0 as well as the chicken
andXenopus laevis integrin sequences (45). Also, all 12 potential N-linked glycosy-
lation sites are conservedbetweenthe human and mouseVLA (3chains. These data
establish XMFNRO-3 as a true VLA a chain clone.
Tissue Distribution.
￿
In man, VLA-5 is part of the VLA family and in some cells
is absent or is a minor component ofthe total VLAs present. To assess relative ex-
pression ofeach chain in mouse tissue, total RNA was isolated from various organs
ofadult mice and analyzed by Northern blotting (Fig. 3). High level expression of
the a chain was restricted to thioglycollate-elicited PECs and was undetectable by
this method in other tissues. Using poly(A)+ RNA, VLA-5a chain transcripts could
be detected atlowlevels in heart, lung, spleen, kidney, andliver, but not brain (data
not shown). VLA (3 chain message was expressed at relatively high levels in heart,
kidney, brain, and lung. No VLA /3 chain message was detected by this method in
mouse spleen although it could be seen in poly(A)+ RNA. Interestingly, two sizes
ofVLA (3 chain message were present (Figs. 3 and 4), a phenomenon not demon-
strated in human cells. This most likely reflects alternate polyadenylation, as there
is a second potential polyadenylation site -600 by 5' ofthe end ofthe cDNA. 0-ac-
tin probinganalysis ofthis blot (Fig. 3) showsvariable levels asexpected, butdemon-
strates no significant degradation of RNA that might account for the differences
intranscript levels . In wholetissue, therefore, VLAachain expression predominates
andis likely to be associatedwith a mouse VLAa chain family similartothe human
family.
Regulation ofExpression in Elicited Macrophages.
￿
Because ofthe high level ofVLA-5
expression in thioglycollate-elicited PECs, we examined the endogenous expression
ofVLA-5 inperitoneal macrophages and its induction by severalinflammatory stimuli
in vivo. Instillationofthioglycollate broth, peptone, or Listeriamonocytogenes intoHOLERS ET AL.
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themouse peritoneum isreported tolead to anincreased number ofperitoneal mac-
rophages with an "activated" phenotype (reviewed in references 48 and 49). Activa-
tion refers to increased abilities to ingest and kill organisms, kill tumor cells, or in-
crease la expression.
To perform ourstudies, equal amounts oftotal RNA ofresident, peptone-elicited,
andthioglycollate-elicited PECs were subjected to Northern blot analysis. Compar-
ison ofVLA-5a and VLAa chain expression in total PECs demonstrated approxi-
mately a three- to fourfold increase in VLA-5a chain expression in thioglycollate-
elicited cells compared with resting peritoneal cells (data not shown). VLA0 chain
message did not change during thioglycollate-elicited inflammation. Because mac-
rophages are only 50-80% of the total PEC population, we further purified them
by adherence for 2 h, isolated total RNA, and repeated the Northern blot analysis
usingequal amountsofRNA in each lane. An example oftheseexperiments is shown
in Fig. 4, and resultsofrelative levels ofexpression ofthe fourprobes used are sum-
marized in Table I. Each experiment was repeated at least three times by indepen-
dent isolation of cells and blot analysis. Relative expression was calculated using
laser densitometry and normalizing values to 1.0 in resting cells for each probe.
The resultsdemonstrate a 10-fold increase inVLA-5achain messagein thioglycol-
late-elicited macrophages relative to steady state levels in resting peritoneal macro-
phages. This increase was specific for VLA-5a, sincea actin and Ia message levels
were minimally altered or actually decreased. Interestingly, VLA a chain message
levels were alsounaltered inthe thioglycollate-elicited cells, suggesting independent
regulation ofVLA-5a and VLA0 chain transcript levels. A reproducible approxi-
mately threefoldincrease inVLA-5achainmessage expression was seen inpeptone-
elicited cells. Time course experiments indicated that the VLA-5a chain message
increase was seenby48 hin thioglycollate-elicited cellsand remained constant through
at least 96 h (data not shown). Because la expression decreased as VLA-5a chain
expression increasedinthethioglycollate-elicited cells, weevaluatedtheeffect ofListeria
infection, a potent inducer of Ia expression, to determine whether VLA-5a and la
message levels were reciprocally regulated. As can be seen in Fig. 4 and is summa-
rized in Table I, Listeria infection led to a sixfold increase in VLA-5a chain mes-
sage, whileIaexpressionwasincreased fourfold. Thisdemonstrated that Ia andVLA-
5a are independently, rather than reciprocally, regulated. Since IFN-T is the major
cytokine responsiblefor enhancingIaexpression, it is unlikely that IFN-,y is a major
factor in regulation ofmacrophage expressionofVLA-5a. Aswas seenin thioglycollate-
induced inflammation, Listeria infection did not significantly alter VLA (3 chain
messagelevels. There was also no significant alteration in the expression ofCHO-B
message in the thioglycollate-, peptone-, or Listeria-elicited macrophages compared
with resting cells (data not shown).
Immunoprecipitation ofMurine VLA-5.
￿
To determine whetherVLA-5 surface pro-
tein expression on adherent macrophages was altered in parallel with the VLA-5a
chain message, we immunoprecipitated surface-labeled cells using Ab33. Because
wehad determined that the mouse intracytoplasmic sequence is identical to human
sequence, we were able to use this specific anticytoplasmic domainpeptide antibody
to identify the receptor on PECs (Fig. 5). After surface labeling adherent macro-
phages with "I and immunoprecipitation ofsolubilized membranes with this an-1596
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tibody, analysis by SDS-PAGE revealed bands with the electrophoretic characteris-
tics similar to human VLA-5 (Fig. 5, lanes 4 and 8). This included a doublet of
160 and 135 kD under nonreducing conditions and an apparent single broad band
of 150 kD under reducing conditions. Increased mobility of the a chain with reduc-
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FIGURE 2.
￿
A restriction map and sequencing strategy of XMFN"3 is shown above and the
nucleotide andderived protein sequence below. The transmembrane sequence is boxed, andthe
intracytoplasmic sequence is underlined. Potential N-linked glycosylation sites are shown by
asterisks. Potential poly-adenylation sites are underlined. (b) Sequence comparison betweenthe
human and mouse 0 chain sequences. The transmembrane region is boxed, and the identical
intracytoplasmic sequencesareshown. Conservedcysteines areshownby arrowheads. These se-
quence data have been submitted to the EMBL/GenBank Data Libraries under the accession
number Y00818.
tion has been primarily attributed to therelease ofa small COOH-terminal L chain
fragment. This suggests that, despite thedifferences in amino acid sequence between
mouse and human VLA-5a chain around the proposed cleavage site, proteolytic
processing of VLA-5ci occurs in murine cells. Decreasedmobility oftheVLA a chain
is presumed due to reduction of disulfide bonds in the cysteine-rich region. The
electrophoretic mobility in these cells appears similar to that of the Fn receptor de-
tected in a mouse pre-B cell line (50).
In comparison of expression ofVLA-5 on resident macrophages to thioglycollate-
elicited macrophages (Fig. 5, lanes 2 and 6vs. lanes 4 and 8), it is readily apparent1598 EXPRESSION OF MURINE PERITONEAL MACROPHAGE VLA-5
TABLE I
Laser Densitometric Analysis by Northern Blot
FIGURE 3 . Tissue distribution Northern blot
analysis using 15 ug oftotal RNA per lane . Probes
used sequentially on this single blot are the in-
serts ofpBSMFNRa-14(a), pBSMFNR0-3(0),
and 0-actin (actin) . The presence of two tran-
scripts in lane 3 (heart) most likely represents
crosshybridization ofthiscDNA probe to smaller
cardiac a-actin transcripts, as has been previously
demonstrated (58) . Tissues of origin are : Lane
1 ; thioglycollate-elicited PECs; lane 2, lung; lane
3, heart ; lane 4, spleen ; lane 5, brain ; and lane
6, kidney . Sizes of transcripts are shown at left.
FIGURE 4 .
￿
Northern blot analysis using 15 jig of total
RNA of adherent PECs isolated as resident (lane 1),
thioglycollate elicited (lane 2), peptone elicited (lane 3),
or Listeria monocytogenes elicited (lane 4). Probes used
sequentially on this single blot are the same as Fig. 3
with the addition of an la probe (see Materials and
Methods) . Sizes of individual transcripts are shown at
left .
Stimulus
Data from laser densitometric analysis of relative expression ofeach gene by North-
ern blot analysis is summarized as the mean and range . n 3 3 for all conditions
except Listeria 0 chain and la expression . All resting macrophage values were
normalized to 1 .0 for these comparisons .
Probe Resident Thioglycollate Peptone Listeria
pBSMFNRa-1 .4 1 .0 10 .8 (6.9-18.3) 3 .1 (2.0-4 .9) 5 .7 (4.9-6.6)
pBSMFNRO-3 1 .0 1 .1 (0.5-1 .4) 1 .7 (0.9-2 .6) 1 .1 (1 .05,1 .09)
la 1 .0 0.26 (0.1-0 .5) 1 .4 (0.9-2 .1) 4 .0 (3 .2,5 .0)
/3-actin 1 .0 2 .2 (1 .5-2 .6) 1 .4 (1 .3-1 .5) -HOLERS ET AL .
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FIGURE 5 .
￿
Immunoprecipitation of surface-labeled adherent resident (lanes 1, 2, 5, and 6) or
thioglycollate elicited (lanes 3, 4, 7, and 8) macrophages . Ab33 was used in lanes 2, 4, 6, and
8and the control antiserum in lanes 1, 3, 5, and 7 . Precipitates were nonreduced in lanes 1-4
and reduced in lanes 5-8 . Molecular weights are shown at the left . VLA-5 bands are demon-
strated in lanes 4 and 8 by arrows .
that thedifferences in expression seen usingNorthern blot analysis are also reflected
in surface expression of the receptor. In the resting state, little or no receptor is de-
tectable by this method, whereas receptor is easily detected in immunoprecipitates
from thioglycollate-elicited adherent cells .
Discussion
In this report, we have characterized a partial cDNA clone encoding the mouse
VLA-5a chain and a full coding clone of the mouseVLA /3 chain . Comparison of
mouse to human VLA-5a chain sequence demonstrates astriking complete conser-
vation of the intracytoplasmic sequence . As this is also seen with (3 chain sequence,
a strong evolutionary drive must be exerted to maintain this identity of both chains,
suggesting that each may play an important role in VLA-5 function . The sequence
conservation ofa and (3 chains also likely indicates structural constraints on the evo-
lution of the entire intracytoplasmic domain ofboth chains, presumably to interact
with each other and/or with other highly conserved sequences of intracytoplasmic
or membrane-associated proteins .
Although there is more sequence divergence about the putative VLA-5a chain1600
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cleavage site, a chain cleavage appears to occur in these cells. This is indicated by
the appropriate increase in a chain mobility on reducing SDS-PAGE (Fig. 5, lane
8). In some instances of protein cleavage (for example, signal peptide cleavage),
hydrophobicity about the cleavage site plays a major role in the signal forcleavage.
Analysis ofhydrophobicity plots about thea chain cleavage site reveal no significant
difference precedingthecleavage site betweenmouse and human VLA-5a. Thehighly
charged lysine-arginine dipeptide, which is immediately NH2 terminal of the puta-
tive human cleavage site, is also conserved.
A comparison of VLA (3 chain sequence between mouse and human reveals a
high degree ofsequence homology as well as complete intracytoplasmic sequence
identity with human, chicken, and Xenopus sequence. Interestingly, all ofthe potential
N-linked glycosylation sites are conservedbetween mouse and human sequence. This
may indicate some important role ofglycosylation in the stable association ofa and
a chains with each otheror with Fn. The overall high degree ofhomology ofhuman
and mousea chains suggests the possibility that the human a chain could associate
with the mouse a chain to form an intact VLA-5 protein, but this remains to be
formally tested.
Comparison of our partial murine VLA-5a chain sequence with other integrin
achain sequences reveals lowbut significantlevels ofhomology (23-40%) (datanot
shown), as has been notedpreviously comparingthese sequencesto humanVLA-5a
chain sequence (51-54). This isnot surprisinginlightofthe high degree ofhomology
between the human and murine VLA-5a chain sequence. Comparison of murine
VLA(3chain sequence withthe othertwo integrin(3 chain sequences, human Mac-1
/3 chain and human gpIIIa (55-57), reveals -45% homology to both(datanot shown).
This degree ofhomology has also been previously notedcomparing these threehuman
a chain sequences.
Of most interest is the increased expression of a chain mRNA induced by two
nonspecific inducers ofinflammation, thioglycollate and Listeria. A less pronounced
but reproducible increase was also found using peptone, another inflammatory
stimulus. This increase is seen without specific change in /3 chain message expres-
sion, in two other control genes (a-actin and CHO-B), and with an appropriate in-
crease in la expression using Listeria. Immunoprecipitation analysis also demon-
strates that surface expression ofVLA-5 is increased in thioglycollate-elicited cells.
It is tempting to speculate that there is a correlation between the observed in-
crease in mouse VLA-5 expression in thioglycollate-elicitedperitoneal macrophages,
the high phagocytic activity ofthese cells, and in vitro experiments demonstrating
enhanced phagocytosis by human macrophages after interaction with Fn. Whether
Fn-mediated phagocytosis enhancement is mediated via this receptor or whether
other Fn receptors primarily mediate this effect is incompletely understood and is
the subject ofongoing experiments in our laboratories. The role ofincreased mu-
rine VLA-5 expression in thioglycollate-elicited macrophages may be to mediate
chemotaxis to Fn fragments, adherence to inflammatory sites, or combinations of
these or otherinflammatory functions. Further study should allowus to answer these
questions using this in vivo model.
This alteration in VLA-5a chain message without change in VLA0 chain mes-
sage leads us to conclude that the two genes are regulated differently and that, atHOLERS ET AL.
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least for inflammatory stimuli, alteration of surface receptor expression correlates
most closely with changes in VLA-5a chain message. This may occur via two pos-
sible mechanisms . One possibility is that multiple VLAs are expressed on macro-
phages and that stimuli that enhance VLA-5 expression coordinately decrease ex-
pressionofother, as yet unidentified, VLA achains. This wouldleave the requirement
forVLAa chainexpression unchanged in resting and activated cells and thus might
leave messagelevels unaffected. On the other hand, it is possible that there is a large
intracellular pool ofVLA/3 chains in restingcells that can combine with newly syn-
thesizeda chains, allowing surfaceexpression ofany particular VLA to be regulated
exclusively by transcription ofthe relevant a chain gene. Further work is required
to distinguish these possibilities, but biosynthetic experimentsin fibroblasts demon-
stratingalarge intracellularpool ofVLA (3 chains (57) are consistent with the latter
hypothesis.
Finally, our data suggest that VLA-5 expression is regulated independently ofIa.
Since Ia expression is dependent on IFN--y, it is unlikely that IFN--y plays a major
rolein regulation ofVLA-5. Whereas manyothercytokines are potential regulators,
our recent work suggests that VLA-5a chain message expression can increase simi-
larly during in vitro culture of resting peritoneal macrophages (data not shown).
This points to the possible role ofan autocrine or paracrine pathway related to mac-
rophage secretion ofcytokines such as IL-1 or TNF, or to the synthesis of Fn itself.
The marked increase in VLA-5a chain expression during inflammation points to
a potentially important role for this receptor in the inflammatory process.
Summary
Human fibronectin receptor (VLA-5) a and (3 chain probes were used to identify
their mouse homologues in a thioglycollate-elicited peritoneal exudate cell cDNA
library. Sequence analysis of both a and /3 chain-related murine clones revealed
-90% homology to theirhuman counterparts by both nucleotide andderived amino
acid sequence comparisons. Detectable a chain transcriptswere seen predominantly
in total RNA ofperitoneal macrophages. /3 chain expression, however, was detected
at higher levels in lung, heart, brain, and kidney, suggesting the presence ofa large
murine VLA family similar to the human family. Analysis of levels of expression
comparing resting peritoneal macrophages with macrophages elicited usinginflam-
matory stimuli indicated that a chain message and surface VLA-5 expression were
significantly increased using thioglycollate or Listeria monocytogenes as stimuli to
elicit cells. Interestingly, 0chainmessagewasunaffectedby these inflammatory stimuli,
suggesting that VLA-5 expression is regulated by VLA-5 a chain message levels.
These resultsindicate thatmacrophage VLA-5 expression can be modulated in vivo
and may provide an important mechanism by which macrophages are recruited to
or adhere to fibronectin in inflammatory foci.
We thank Pat Parvin for expert secretarial assistance, Barb Gruner for technical help in se-
quencing, andPaul Allen andRobin Lorenz for providinghelp with macrophage purification
and mice for the Listeria experiments.
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